According to Franklin Covey's latest financial reports the company has a price-to-book ratio of 7.44.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 8.20 | 13.03% |
2022-12-31 | 7.25 | -10.24% |
2021-12-31 | 8.08 | 51.86% |
2020-12-31 | 5.32 | 0.67% |
2019-12-31 | 5.28 | 30.59% |
2018-12-31 | 4.05 | 15.56% |
2017-12-31 | 3.50 | 14.46% |
2016-12-31 | 3.06 | 43.08% |
2015-12-31 | 2.14 | -16.2% |
2014-12-31 | 2.55 | -18.27% |
2013-12-31 | 3.12 | 23.12% |
2012-12-31 | 2.54 | 38.58% |
2011-12-31 | 1.83 | -9.58% |
2010-12-31 | 2.02 | 32.86% |
2009-12-31 | 1.52 | 16.18% |
2008-12-31 | 1.31 | -14.05% |
2007-12-31 | 1.53 | 46.19% |
2006-12-31 | 1.04 | -0.08% |
2005-12-31 | 1.04 | 255.44% |
2004-12-31 | 0.2938 | -4.6% |
2003-12-31 | 0.3080 | 198.03% |
2002-12-31 | 0.1033 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Spero Therapeutics SPRO | 0.7361 | -90.11% | ๐บ๐ธ USA |
Universal Technical Institute UTI | 3.68 | -50.59% | ๐บ๐ธ USA |